Journal article icon

Journal article

Adenylyl cyclase isoform 1 contributes to sinoatrial node automaticity via functional microdomains

Abstract:
Sinoatrial node (SAN) cells are the heart's primary pacemaker. Their activity is tightly regulated by β-adrenergic receptor (β-AR) signaling. Adenylyl cyclase (AC) is a key enzyme in the β-AR pathway that catalyzes the production of cAMP. There are current gaps in our knowledge regarding the dominant AC isoforms and the specific roles of Ca2+-activated ACs in the SAN. The current study tests the hypothesis that distinct AC isoforms are preferentially expressed in the SAN and compartmentalize within microdomains to orchestrate heart rate regulation during β-AR signaling. In contrast to atrial and ventricular myocytes, SAN cells express a diverse repertoire of ACs, with ACI as the predominant Ca2+-activated isoform. Although ACI-KO (ACI-/-) mice exhibit normal cardiac systolic or diastolic function, they experience SAN dysfunction. Similarly, SAN-specific CRISPR/Cas9-mediated gene silencing of ACI results in sinus node dysfunction. Mechanistically, hyperpolarization-activated cyclic nucleotide-gated 4 (HCN4) channels form functional microdomains almost exclusively with ACI, while ryanodine receptor and L-type Ca2+ channels likely compartmentalize with ACI and other AC isoforms. In contrast, there were no significant differences in T-type Ca2+ and Na+ currents at baseline or after β-AR stimulation between WT and ACI-/- SAN cells. Due to its central characteristic feature as a Ca2+-activated isoform, ACI plays a unique role in sustaining the rise of local cAMP and heart rates during β-AR stimulation. The findings provide insights into the critical roles of the Ca2+-activated isoform of AC in sustaining SAN automaticity that is distinct from contractile cardiomyocytes
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1172/jci.insight.162602

Authors

More by this author
Role:
Author
ORCID:
0000-0002-9731-8562
More by this author
Role:
Author
ORCID:
0000-0001-7344-150X
More by this author
Role:
Author
ORCID:
0000-0003-2273-0453


More from this funder
Funder identifier:
10.13039/100000968
Grant:
18PRE34030199
More from this funder
Funder identifier:
10.13039/100000738
Grant:
I01 BX000576,I01 CX001490
More from this funder
Funder identifier:
10.13039/501100000274
Grant:
PG/15/5/31110,RG/17/6/32944
More from this funder
Funder identifier:
10.13039/100000002
Grant:
NIH R01 HL085844,NIH R01 HL137228,NIH S10 OD010389,NIH R01 HL085727,NIH T32 HL086350,NIH F32 HL149288,NIH R56 HL138392,NIH P01 AG051443,NIH R01 DC015252,NIH R01 DC015135,NIH HL147263,NIH R01HL098200,R01HL149127


Publisher:
American Society for Clinical Investigation
Journal:
JCI Insight More from this journal
Volume:
7
Issue:
22
Pages:
e162602
Article number:
e162602
Publication date:
2022-11-21
DOI:
EISSN:
2379-3708
ISSN:
2379-3708


Language:
English
Keywords:
Pubs id:
1316645
Local pid:
pubs:1316645
Source identifiers:
W4309497287
Deposit date:
2026-04-30
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP